Michael Barbella, Managing Editor03.28.23
Myomo Inc. has appointed Yitzchak Jacobovitz as a Class II director on its board, serving a two-year term. With this appointment, Myomo's Board of Directors has six members.
Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates (AIGH), where he has significantly grown AIGH’s healthcare footprint since joining in 2014. Prior to AIGH, Jacobovitz was a managing director at Capstone, a policy research firm, and an analyst at Leap Tide Capital, a special situations hedge fund.
Jacobovitz earned his MBA from Johns Hopkins University and is a chartered financial analyst.
“We welcome Yitz to the Myomo Board of Directors and are gratified that AIGH was the lead investor in our most recent equity offering,” Myomo CEO/Chairman Paul R. Gudonis said. "Yitz brings extensive healthcare investment experience to our board and we look forward to his contributions as we build value for our stockholders."
Myomo Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, with sales and clinical professionals across the United States and representatives internationally.
Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates (AIGH), where he has significantly grown AIGH’s healthcare footprint since joining in 2014. Prior to AIGH, Jacobovitz was a managing director at Capstone, a policy research firm, and an analyst at Leap Tide Capital, a special situations hedge fund.
Jacobovitz earned his MBA from Johns Hopkins University and is a chartered financial analyst.
“We welcome Yitz to the Myomo Board of Directors and are gratified that AIGH was the lead investor in our most recent equity offering,” Myomo CEO/Chairman Paul R. Gudonis said. "Yitz brings extensive healthcare investment experience to our board and we look forward to his contributions as we build value for our stockholders."
Myomo Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, with sales and clinical professionals across the United States and representatives internationally.